Integra Lifesciences ( (IART) ) has released its Q1 earnings. Here is a breakdown of the information Integra Lifesciences presented to its investors.
Integra LifeSciences Holdings Corporation is a global medical technology company specializing in surgical, neurologic, and regenerative care, offering a comprehensive portfolio of high-quality, leadership brands.
Integra LifeSciences reported its financial results for the first quarter of 2025, highlighting a 3.7% increase in reported revenues to $382.7 million, although organic revenues declined by 3.5%. The company also announced a GAAP net loss of $25.3 million, with adjusted earnings per diluted share at $0.41, down from $0.55 in the previous year.
Key financial metrics for the quarter included a GAAP gross margin of 50.8%, down from 56.1% in the prior year, and an adjusted gross margin of 62.2%. The Codman Specialty Surgical segment, which accounts for approximately 70% of revenues, saw a reported growth of 9.4%, while the Tissue Technologies segment experienced a decline of 9.3%. The company is focused on improving supply reliability and operational excellence through its Compliance Master Plan and the establishment of a Transformation and Program Management Office.
Looking ahead, Integra LifeSciences reaffirmed its full-year 2025 revenue guidance, expecting reported growth between 2.4% and 6.5%. However, the company adjusted its earnings per share guidance to account for the impact of new tariffs, projecting adjusted EPS between $2.19 and $2.29 for the year.
Integra LifeSciences remains committed to enhancing its quality systems and operational execution, aiming to deliver long-term value for patients, customers, and shareholders as it navigates the challenges of the current economic environment.